Clinical trial · Observational
Clinical Predictors of Survival in Cancer Patients With Metastatic Solid Tumors
Investigator Initiated Trial: Prospective Study of Clinical Predictors of Survival in Cancer Patients With Metastatic Solid Tumors
NCT00322634CI-TRIAL-00008045completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The use of performance status and LDH in combination can predict patient survival more accurately than physician clinical impression or the patients' own feelings about their survival
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Disease Progression
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. All patients must be at least 18 years of age 2. All patients must have documented incurable metastatic cancer 3. All patients must have exhausted any treatments which are known to prolong survival in their disease, or have elected not to receive further life-prolonging therapy. Specifically, patients with the following are eligible: 1. Non-small cell lung cancer patients after third systemic therapy 2. Small cell lung cancer patients after second systemic therapy 3. Breast cancer patients after third cytotoxic therapy (does not include hormonal therapy) 4. Colorectal cancer patients after second systemic therapy 5. Hormone refractory prostate cancer patients after first cytotoxic therapy 6. Cancer of unknown primary 7. Pancreatic cancer patients after first systemic therapy 4. The use of systemic (chemotherapy, immunotherapy) or local treatments (XRT) for palliation of symptoms is allowed 5. Patients with a history of previous cancers are allowed 6. Patients with a history of other significant disease (e.g. heart disease, COPD, etc.) are allowed 7. All patients must sign informed consent Exclusion Criteria: 1. Patients with acute or chronic leukemia, Hodgkin's disease, or non-Hodgkins lymphoma are excluded 2. Patients who do not sign informed consent are excluded
References
Publications (0)
Data not yet available
No reference posted for this study.